News from regeneron pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jan 26, 2015, 01:00 ET

Regeneron and Sanofi Announce Praluent™ (alirocumab) Biologics License Application has Been Accepted for Priority Review by US FDA

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for...

Jan 23, 2015, 07:32 ET

EYLEA® (aflibercept) Injection Recommended for Approval for the Treatment of Visual Impairment Due to Macular Edema Secondary to Central or Branch Retinal Vein Occlusion in the European Union

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that EYLEA® (aflibercept) Injection has been recommended for approval by...

Jan 12, 2015, 01:00 ET

Regeneron and Sanofi Announce Praluent™ (alirocumab) Marketing Authorization Application has Been Accepted for Review by EMA

 Regeneron (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency (EMA) has accepted for review the Marketing...

Jan 09, 2015, 09:30 ET

Regeneron to Report Fourth Quarter and Full Year 2014 Financial and Operating Results and Host Conference Call and Webcast on February 10, 2015

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its fourth quarter and full year 2014 financial and...

Jan 09, 2015, 01:00 ET

Regeneron and Sanofi Announce Positive Topline Results from First Phase 3 Trials Evaluating Monthly Dosing of Alirocumab in Patients with Hypercholesterolemia

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that two new ODYSSEY trials, which are the first Phase 3 trials to assess...

Dec 19, 2014, 09:30 ET

Regeneron Announces Presentation and Panel Discussion at the 33rd Annual J.P. Morgan Healthcare Conference

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the 33rd Annual J.P. Morgan Healthcare Conference...

Dec 15, 2014, 08:00 ET
Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol

Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol

  Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi US (EURONEXT: SAN and NYSE: SNY) are collaborating with nationally-recognized...

Dec 01, 2014, 07:00 ET

EYLEA® (aflibercept) Injection Accepted for Priority Review by FDA for Diabetic Retinopathy in Patients with Diabetic Macular Edema

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

Nov 20, 2014, 01:30 ET

Regeneron and Sanofi Announce that Dupilumab Has Received FDA Breakthrough Therapy Designation in Atopic Dermatitis

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has granted...

Nov 19, 2014, 08:15 ET

Regeneron and Sanofi Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced new detailed positive results from six Phase 3 ODYSSEY trials that...

Nov 19, 2014, 08:15 ET
Sanofi

Sanofi and Regeneron Announce New Results from Six Phase 3 Trials Showing that Alirocumab Significantly Reduced LDL Cholesterol

 Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced new detailed positive results from six Phase 3 ODYSSEY trials that...

Nov 18, 2014, 03:05 ET

Regeneron Announces EYLEA® (aflibercept) Injection Approved for the Treatment of Diabetic Macular Edema (DME) in Japan

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received...

Nov 11, 2014, 01:00 ET

Regeneron and Sanofi Announce Positive Results from Phase 2b Study of Dupilumab in Patients with Moderate-to-Severe Asthma

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from the interim...

Nov 04, 2014, 06:30 ET

Regeneron Reports Third Quarter 2014 Financial and Operating Results

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the third quarter of 2014 and provided an update on...

Nov 03, 2014, 16:01 ET

Regeneron Announces Upcoming 2014 Investor Conference Presentations

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences: - Credit...

Oct 20, 2014, 07:00 ET

Regeneron and Sanofi Announce Start of Phase 3 Study of Dupilumab in Patients with Atopic Dermatitis

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced that the first patients have been...

Oct 17, 2014, 07:00 ET

EYLEA® (aflibercept) Injection Demonstrates Significantly Greater Gains in Visual Acuity than Both Bevacizumab and Ranibizumab in NIH-Sponsored Diabetic Macular Edema Study

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that in the National Institutes of Health (NIH) sponsored, Diabetic Retinopathy...

Oct 16, 2014, 14:00 ET

Regeneron Ranked Number One Biopharmaceutical Employer by Science Magazine for Third Consecutive Year

 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced it has been recognized by Science Magazine as the number one employer in the...

Oct 16, 2014, 08:30 ET

Regeneron Genetics Center Fully Operational, Announces New Collaborations and Key Appointments

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the Regeneron Genetics Center LLC (RGC), a wholly-owned subsidiary, has...

Oct 15, 2014, 16:01 ET

Regeneron to Report Third Quarter 2014 Financial and Operating Results and Host Conference Call and Webcast on November 4, 2014

 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2014 financial and operating results...